Clinical performance of prostate health index in men with tPSA>10 ng/ml: Results from a multicentric European study
详细信息 查看全文
- 作者：Massimo Lazzeri ; M.D.a ; 1 ; Giovanni Lughezzani ; M.D.a ; 1 ; giovanni.lughezzani@humanitas.it" class="auth_mail" title="E-mail the corresponding author ; Alexander Haese ; M.D.b ; Thomas McNicholas ; M.D.c ; Alexandre de la Taille ; M.D.d ; Nicolò ; Maria Buffi ; M.D.a ; Pasquale Cardone ; M.D.a ; Rodolfo Hurle ; M.D.a ; Paolo Casale ; M.D.a ; Vittorio Bini ; M.D.e ; Joan Palou Redorta ; M.D.f ; Markus Graefen ; M.D.b ; Giorgio Guazzoni ; M.D.a ; g
- 关键词：Prostate health index ; PHI ; Prostate cancer ; Prostate biopsy ; High total PSA
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：34
- 期：9
- 页码：415.e13-415.e19
- 全文大小：469 K
文摘
- •
The current study supported the diagnostic accuracy of PHI in patients with high (>10 ng/ml) tPSA levels.
- •
The inclusion of PHI in the biopsy decision path of these patients would decrease the number of unnecessary biopsies by an extent of 50.0%, while missing only few cases with clinically significant PCa.
- •
As this marker is also associated with cancer aggressiveness, high percentage of PHI levels should guide the subsequent diagnostic and therapeutic approaches.